Menu

Infographic: Cancer Drug Pairings

Researchers use several different strategies to deliver a one-two punch.

Mar 31, 2018
Anna Azvolinsky

Among the first cancer drug combinations were mixtures of several chemotherapies that resulted in better and longer-lasting responses than individual drugs could deliver. Then came targeted therapies and immunotherapies, which were combined with chemotherapies and with each other to increase the proportion of patients who respond and the duration of those responses. While many cancer drug combinations were discovered by empirically testing opportunistic and random pairings, others were based on biological hypotheses that one drug could complement the other. Below are a few of the strategies behind recently successful and still investigational combos. 

Doubling Up on Targeted Therapy

Coadministering two targeted agents that work on different targets within the same signaling pathway is a way to stave off cancer resistance. Combining two targeted agents that block molecules within different pathways is one common strategy.

EXAMPLE: In 2014, the FDA approved the first combination: dabrafenib, a B-raf inhibitor, plus trametinib, a MEK inhibitor, for advanced melanoma. The two drugs target different molecules within the Ras signaling pathway (left). The combination of lenvatinib, an anti-VEGF oral drug, and everolimus, an oral mTOR inhibitor, was approved by the FDA for renal cell carcinoma in 2016. The drugs target two separate but cancer-linked signaling pathways that support tumor growth (right).© THOM GRAVES

Immunotherapy-Chemotherapy, Radiation, or Targeted Therapy.

As chemotherapy, radiation, or targeted therapies kill cancer cells, neoantigens are released, helping the immune system recognize tumor cells. These therapies also minimize tumor burden, buying time for the immune system to act. Simultaneously, checkpoint inhibitors ramp up the immune response.

EXAMPLE: In 2017, the FDA approved the combination of the chemotherapies pemetrexed and carboplatin, plus the checkpoint inhibitor pembrolizumab, for advanced lung cancer.© THOM GRAVES

Immunotherapy-immunotherapy

DUAL CHECKPOINT INHIBITOR ANTIBODY COMBINATION: Combining two checkpoint inhibitors that target two different checkpoint pathways is one strategy to stimulate a greater and possibly more durable antitumor immune response.

EXAMPLE: The only currently a pproved immunotherapy combination is ipilimumab plus nivolumab for metastatic melanoma. Other checkpoint inhibitor combinations arecurrently in clinical trials.

© THOM GRAVESCHECKPOINT INHIBITOR PLUS A CELL-BASED THERAPY: Also seen as a way to target two different pathways to amplify the immune response and potentially overcome resistance.

EXAMPLE: Still theoretical, with no combinations yet approved or in clinical trials
© THOM GRAVES
CHECKPOINT INHIBITOR PLUS A VIRAL VACCINE: A vaccine, in theory, should increase the presentation of cancer neoantigens to the immune system, bolstering the immune system’s response to a checkpoint inhibitor.

EXAMPLE: The cancer vaccine talimogene laherparepvec, a genetically engineered herpes virus, plus ipilimumab is currently in a Phase 2 trial for advanced melanoma, with some positive preliminary data.
© THOM GRAVES

Read the full story.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.